In the last trading session, 1.01 million Immunome Inc (NASDAQ:IMNM) shares changed hands as the company’s beta touched 1.94. With the company’s per share price at $9.67 changed hands at $0.32 or 3.42% during last session, the market valuation stood at $818.81M. IMNM’s last price was a discount, traded about -220.17% off its 52-week high of $30.96. The share price had its 52-week low at $8.97, which suggests the last value was 7.24% up since then.
Analysts gave the Immunome Inc (IMNM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IMNM as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Immunome Inc’s EPS for the current quarter is expected to be -0.67.
Immunome Inc (NASDAQ:IMNM) trade information
Instantly IMNM was in green as seen at the end of in last trading. With action -2.62%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -8.95%, with the 5-day performance at -2.62% in the red. However, in the 30-day time frame, Immunome Inc (NASDAQ:IMNM) is -2.81% down.
The consensus price target for the stock as assigned by Wall Street analysts is 33, meaning bulls need an upside of 70.7% from its current market value. According to analyst projections, IMNM’s forecast low is 23 with 35 as the target high. To hit the forecast high, the stock’s price needs a -261.94% plunge from its current level, while the stock would need to soar -137.85% for it to hit the projected low.
Immunome Inc (IMNM) estimates and forecasts
Year-over-year growth is forecast to reach -32.90% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 3.16M. 6 analysts are of the opinion that Immunome Inc’s revenue for the current quarter will be 515.67k. The company’s revenue for the corresponding quarters a year ago was 3.83M and 1.03M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -17.51%. The estimates for the next quarter sales put growth at -49.89%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -48.48%. The 2025 estimates are for Immunome Inc earnings to increase by 17.82%, but the outlook for the next 5-year period is at 16.01% per year.
IMNM Dividends
Immunome Inc is expected to release its next quarterly earnings report in March.
FMR LLC holds the second largest percentage of outstanding shares, with 7.0257% or 4.21 million shares worth $50.95 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Price (T.Rowe) Small Cap Stock Fund and Vanguard Total Stock Market Index Fund . With 2.07 shares estimated at $20.01 million under it, the former controlled 3.31% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.62% of the shares, roughly 1.64 shares worth around $15.84 million.
